Description
Immediately after intravenous administration, immunoglobulin is completely bioavailable in the patient's circulation. It is distributed relatively rapidly between plasma and extravascular fluid, reaching approximately after 35 days a balance between the intravascular and extravascular compartments. Clinical experience with immunoglobulins indicates that no harmful effects should be expected during pregnancy, in the fetus or in the newborn.